PARAGON: a phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors

- Tang, Monica, O'Connell, Rachel L., Amant, Frederic, Beale, Philip, McNally, Orla, Sjoquist, Katrin M., Grant, Peter, Davis, Alison, Sykes, Peter, Mileshkin, Linda, Moujaber, Tania, Kennedy, Catherine J., deFazio, Anna, Tan, King, Antill, Yoland, Goh, Jeffrey, Bonaventura, Tony, Scurry, James, Friedlander, Michael

Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: the PARAGON trial – ANZGOG 0903

- Mileshkin, Linda, Edmondson, Richard, O'Connell, Rachel L., Sjoquist, Katrin M., Andrews, John, Jyothirmayi, Rema, Beale, Philip, Bonaventura, Tony, Goh, Jeffrey, Hall, Marcia, Clamp, Andrew, Green, John, Lord, Rosemary, Amant, Frédéric, Alexander, Laura, Carty, Karen, Paul, James, Scurry, James, Millan, David, Nottley, Steven, Friedlander, Michael

Paragon (ANZGOG-0903): phase 2 study of Anastrozole in women with estrogen or progesterone receptor-positive platinum-resistant or -refractory recurrent ovarian cancer

- Bonaventura, Anthony, O'Connell, Rachel L., Martyn, Julie, DeFazio, Anna, Scurry, James, Friedlander, Michael L., Mapagu, Cristina, Beale, Philip J., McNally, Orla M., Mileshkin, Linda R., Grant, Peter T., Hadley, Alison M., Goh, Jeffery C. H., Sjoquist, Katrin M.